Indivior (INDV) Stock Price, News & Analysis

Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Key Stats

• Today's Range: $8.38 to $9.02
• 50-Day Range: $8.99 to $12.50
• 52-Week Range: $7.33 to $23.22
• Volume: 1.74 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $1.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Indivior has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 40.16%

Earnings Growth

Earnings for Indivior are expected to grow by 40.16% in the coming year, from $1.22 to $1.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is -24.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is -24.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.23% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indivior has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.23% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indivior has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.19

News Sentiment

Indivior has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Indivior this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Indivior to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have not sold or bought any company stock.

Percentage Held by Institutions

60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INDV Stock Analysis - Frequently Asked Questions

How have INDV shares performed this year?

Indivior's stock was trading at $12.43 on January 1st, 2025. Since then, INDV stock has decreased by 31.9% and is now trading at $8.4650.
View the best growth stocks for 2025 here.

How were Indivior's earnings last quarter?

Indivior PLC (NASDAQ:INDV) released its earnings results on Thursday, February, 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. The company had revenue of $298 million for the quarter, compared to analysts' expectations of $262.35 million. Indivior had a negative net margin of 3.96% and a negative trailing twelve-month return on equity of 241.73%.

Who are Indivior's major shareholders?

Indivior's top institutional investors include Two Seas Capital LP (9.04%), Deerfield Management Company L.P. Series C (6.44%), Oaktree Capital Management LP (6.33%) and Vanguard Group Inc. (3.31%).

How do I buy shares of Indivior?

Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 2/21/2025
• Next Earnings (Estimated): 4/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INDV
• CUSIP: N/A
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 1,164
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +89.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.46
• P/E Growth: N/A
• Net Income: $2 million
• Net Margins: -0.17%
• Pretax Margin: -0.93%
• Return on Equity: -351.08%
• Return on Assets: 15.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.83
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $1.09 billion
• Price / Sales: 1.07
• Cash Flow: $1.41 per share
• Price / Cash Flow: 5.99
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 137,880,000
• Free Float: N/A
• Market Cap: $1.17 billion
• Optionable: Not Optionable
• Beta: 0.73